Authors
Latest:
Link Between Medicaid and Rates of Biomarker Testing in NSCLCCary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.
Latest:
CAR T-Cell Therapy Access Remains Elusive, But Solutions May Be Closer Than ExpectedWidespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.
Latest:
Anti–LAG-3/Anti–PD-1 Combo Demonstrates Sustained Efficacy in MelanomaMeredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.
Latest:
Breaking Down T-Cell Therapies: TCR and CAR T MechanismsPaulina Velasquez, MD, discusses the differences between T-cell receptor-based and chimeric antigen receptor T-cell therapies.
Latest:
Exploring the Benefits of Nab-Sirolimus in Advanced PEComa TreatmentIn an interview with Targeted Oncology, Jacob Stein, MD, MPH, discussed nab-sirolimus and its impact on patients with advanced PEComa.
Latest:
Implications of the EPOCH Trial in Clinical PracticeMary F. Mulcahy discusses the potential implications of the EPOCH trial in clinical practice.
Latest:
Takeaways From CheckMate-649 in Gastric/GEJ/Esophageal CancersRyan Sugarman, MD, discusses the key takeaways from the CheckMate-649 trial of patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receiving nivolumab combined with chemotherapy compared with chemotherapy alone in the first-line.
Latest:
Individualized Approaches and Challenges in MyelofibrosisRaajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.
Latest:
Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Latest:
Case 4: Later Lines of Therapy for Patients With Recurrent HCCExpert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.
Latest:
Future Directions for Treating Stage 1B, Grade 3 Endometrial CancerDavid Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.
Latest:
Exploring Advancements in Higher-Risk MDSDespite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.
Latest:
Hijioka Discusses STARTER-NET: Everolimus Plus Lanreotide in GEP-NETsSusumu Hijioka, MD, discusses the key takeaways from the phase 3 STARTER-NET trial evaluating the combination of everolimus with lanreotide when used for the first-line treatment of patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors.
Latest:
Exploring Therapies in Combination With Cytoreductive Nephrectomy in RCCKetan K. Badani, MD, discusses whether cytoreductive nephrectomies are efficacious when combined with immunotherapeutic agents in patients with renal cell carcinoma.
Latest:
Recommendations and Future Directions of Genetic Testing for CLLSusan L. Slager, PhD, discusses some of the recommendations for genetic testing in individuals with a family history of chronic lymphocytic leukemia.
Latest:
Known Biomarkers, Better Care: Optimizing a CDS Tool to Guide Personalized Cancer TreatmentDaniel Rubin, PharmD, discusses key takeaways from a study exploring the use. of a clinical decision tool for biomarker documentation.
Latest:
Survival Gains and Challenges: The CROSS Trial in GEJ CancerYanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction and esophageal cancers.
Latest:
Updated MAIA Trial Data Show Improved Survival for Multiple MyelomaNizar Bahlis, MD, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.
Latest:
Supporting Cancer Survivors: The Clinician's RoleAmy Selly, CNP, AOCNP, discusses how physicians can support their patients' survivorship journeys.
Latest:
World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and TreatmentLynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.
Latest:
Pembrolizumab’s Potential in Treating Richter Transformation of CLLYucai Wang, MD, PhD, discusses the rationale, methods, and design of a study evaluating the efficacy of pembrolizumab when given as both a monotherapy and in combination with B-cell receptor inhibitors for Richter transformation of CLL.
Latest:
Tazemetostat Shows Benefit in EZH2-Mutated Follicular LymphomaConnie L. Batlevi, MD, PhD, discusses the efficacy of tazemetostat in patients with follicular lymphoma and an EZH2 mutation.
Latest:
Safety Challenges of Oncolytic Virus TherapyAs part of its Speaking Out series, Patrick Wagner, MD, discusses safety concerns regarding oncolytic viral therapy.
Latest:
Where Does Inhibition of BCL-2 Family Proteins Fit into the Multiple Myeloma Treatment Landscape?Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.
Latest:
New Research Challenges ASCT Sequencing in Refractory AMLJohannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia/
Latest:
Novel Agents/Combinations for aRCCMatthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma.
Latest:
Less Toxic, More Personalized Treatments on the Horizon in HER2+ Breast CancerNaomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.
Latest:
Clinical Activity Is Found With Triplet Combination and ADCs in HER2-Mutant MBCResults from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.
Latest:
PR-Driven Approaches to Treating Granulosa Cell TumorsEven though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.
Latest:
PARP Inhibitor Costs Give Patients With Ovarian Cancer Financial ToxicityRoss F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.
